New developments in the era of viral hepatitis vaccines

Merve Poyraz; Osman Cavit Özdoğan

doi:10.5472/MMJsi.2901.06

New developments in the era of viral hepatitis vaccines

Year 2016, , 29 - 32, 01.08.2016

Merve Poyraz Osman Cavit Özdoğan

https://doi.org/10.5472/MMJsi.2901.06

Abstract

Chronic hepatitis B and hepatitis C infections are major healthproblems in the world. Therefore, prevention of the transmission ofthe viral infections gets higher priority. Development of hepatitisB vaccines by recombinant technology provide higher preventionrates. However, this success could not be achieved with hepatitisC vaccine. The present review discusses recent developments forhepatitis B and C vaccines.Keywords: New vaccines, Hepatitis B, Hepatitis C

References

McMahon BJ. Epidemiology and natural history of hepatitis
B. Semin Liver Dis 2005; 25 Suppl 1:3.
Lavanchy D. Hepatitis B virus epidemiology, disease burden
treatment, and current and emerging prevention and control
measures. J Viral Hepat 2004; 11:97.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B
vaccine: demonstration of efficacy in a controlled clinical trial
in a high-risk population in the United States. N Eng J Med
303:833–4.
McAleer WJ, Buynack EB, Maigetter RZ, Wampler DE
Miller WJ, Hilleman MR. Human hepatitis B vaccine from
recombinant yeast. Nature 1984;307:178–80.
Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson
B, Maddrey WC, US Hepacare Study Group, Adult hepatitis
B vaccination using a novel triple antigen recombinant
vaccine. Hepatology 2001;34:372.
Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibodyresponse
to three recombinant hepatitis B vaccines
comparative evaluation of multicenter travel-clinic based
experience. Vaccine 2001; 19:2055-60.
Blatter M, Joines R, Resinger K, et al. An open, randomized
controlled study to evaluate the safety and immunogenicity
of SmithKline Beecham Biologicals’ combined hepatitis A/
hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In
Program and abstracts of the 39th Interscience Conference
on Antimicrobial Agents and Chemotherapy (San Francisco)
American Society for Microbiology, Washington, DC
394.
Abraham B, Parenti D. Antibody production in response
to hepatitis B surface antigen in a combination hepatitis A/
hepatitis B vaccine. J Infect Dis 2000; 182:1005-6.
Hadler SC, Francis DP, Maynard JE, et al. Long-term
immunogenicity and efficacy of hepatitis B vaccine in
homosexual men. N Engl J Med 1986; 315:209-14.
Poland GA. Hepatitis B immunization in health care workers.
Dealing with vaccine nonresponse. Am J Prev Med 1998
73-7.
Propst T, Propst A, Lhotta K, et al. Reinforced intradermal
hepatitis B vaccination in hemodialysis patients is superior
in antibody response to intramuscular or subcutaneous
vaccination. Am J Kidney Dis 1998; 32:1041-5.
Peces R, de la Torre M, Alcázar R, Urra JM. Prospective
analysis of the factors influencing the antibody response to
hepatitis B vaccine in hemodialysis patients. Am J Kidney
Dis 1997; 29:239-45.
Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic
prediction of nonresponse to hepatitis B vaccine. N Engl J
Med 1989; 321:708-12.
Makidon PE, Bielinska AU, Nigavekar SS, et al. Preclinical
evaluation of a novel nanoemulsion-based hepatitis
B mucosal vaccine. PLoS One 2008; 3:e2954. doi: 10.1371/
journal.pone.0002954
Halperin SA, Ward B, Cooper C, et al. Comparison of safety and
immunogenicity of two doses of investigational hepatitis B virus
surface antigen co-administered with an immunostimulatory
phosphorothioate oligodeoxyribonucleotide and three doses
of a licensed hepatitis B vaccine in healthy adults 18-55
years of age. Vaccine 2012; 30:2556-63. doi: 10.1016/j.
vaccine.2012.01.087
Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of
safety and enhanced seroprotection against hepatitis B with
investigational HBsAg-1018 ISS vaccine compared to a
licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. doi
1016/j.vaccine.2012.02.001
Singh M, Li XM, McGee JP, et al. Controlled release
microparticles as a single dose hepatitis B vaccine: evaluation
of immunogenicity in mice. Vaccine 1997; 15:475-81.
Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular
and humoral immune responses induced by intradermal or
intramuscular vaccination with the major hepatitis B surface
antigen. Hepatology 2000; 31:521-7.
Rault R, Freed B, Nespor S, Bender F. Efficacy of different
hepatitis B vaccination strategies in patients receiving
hemodialysis. ASAIO J 1995; 41:M717.
Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis
intradermal vs. intramuscular vaccination against hepatitis
B virus in patients with chronic kidney disease. Aliment
Pharmacol Ther 2006; 24:497-506.
Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in
haemodialysis patients. Lancet 1989; 1:1264.
Jungers P, Devillier P, Salomon H, et al. Randomised
placebo-controlled trial of recombinant interleukin-2 in
chronic uraemic patients who are non-responders to hepatitis
B vaccine. Lancet 1994; 344:856.
Thoelen S, Van Damme P, Mathei C, et al. Safety and
immunogenicity of a hepatitis B vaccine formulated with a
novel adjuvant system. Vaccine 1998; 16:708.
Traquina P, Morandi M, Contorni M, Van Nest G. MF59
adjuvant enhances the antibody response to recombinant
hepatitis B surface antigen vaccine in primates. J Infect Dis
174:1168.
Jacques P, Moens G, Desombere I, et al. The immunogenicity
and reactogenicity profile of a candidate hepatitis B vaccine
in an adult vaccine non-responder population. Vaccine 2002
3644.
Sprengers D, Janssen HLA. Immunomodulatory therapy for
chronic hepatitis B virus infection. Fundam Clin Pharmacol
19:17–26
Tozun N, Ozdogan OC, Cakaloglu Y, et al. A nationwide
prevalance study and risk factors for hepatitis A, B, C and
D infections in Turkey. Hepatology Volume 2010; 52
(Supplement S1): 697A.
Houghton M. Prospects for prophylactic and therapeutic
vaccines against the hepatitis C viruses. Immunol Rev 2011
99–108.
Frey SE, Houghton M, Coates S, et al. Safety and
immunogenicity of HCV E1E2 vaccine adjuvanted with
MF59 administered to healthy adults. Vaccine 2010; 28
-73.
Law LMJ, Landi A, Magee WC, Tyrrell DL, Houghton
H. Progress towards a hepatitis C virus vaccine. Emerging
Microbes and Infections 2013;2:e79. doi:10.1038/
emi.2013.79; published online 20 November 2013

New developments in the era of viral hepatitis vaccines

Year 2016, , 29 - 32, 01.08.2016

Merve Poyraz Osman Cavit Özdoğan

https://doi.org/10.5472/MMJsi.2901.06

Abstract

Keywords

Yeni aşılar, Hepatit B, Hepatit C

References

McMahon BJ. Epidemiology and natural history of hepatitis
B. Semin Liver Dis 2005; 25 Suppl 1:3.
Lavanchy D. Hepatitis B virus epidemiology, disease burden
treatment, and current and emerging prevention and control
measures. J Viral Hepat 2004; 11:97.
Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B
vaccine: demonstration of efficacy in a controlled clinical trial
in a high-risk population in the United States. N Eng J Med
303:833–4.
McAleer WJ, Buynack EB, Maigetter RZ, Wampler DE
Miller WJ, Hilleman MR. Human hepatitis B vaccine from
recombinant yeast. Nature 1984;307:178–80.
Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson
B, Maddrey WC, US Hepacare Study Group, Adult hepatitis
B vaccination using a novel triple antigen recombinant
vaccine. Hepatology 2001;34:372.
Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibodyresponse
to three recombinant hepatitis B vaccines
comparative evaluation of multicenter travel-clinic based
experience. Vaccine 2001; 19:2055-60.
Blatter M, Joines R, Resinger K, et al. An open, randomized
controlled study to evaluate the safety and immunogenicity
of SmithKline Beecham Biologicals’ combined hepatitis A/
hepatitis B (Twinrix®) vaccine in adults (abstract 1629). In
Program and abstracts of the 39th Interscience Conference
on Antimicrobial Agents and Chemotherapy (San Francisco)
American Society for Microbiology, Washington, DC
394.
Abraham B, Parenti D. Antibody production in response
to hepatitis B surface antigen in a combination hepatitis A/
hepatitis B vaccine. J Infect Dis 2000; 182:1005-6.
Hadler SC, Francis DP, Maynard JE, et al. Long-term
immunogenicity and efficacy of hepatitis B vaccine in
homosexual men. N Engl J Med 1986; 315:209-14.
Poland GA. Hepatitis B immunization in health care workers.
Dealing with vaccine nonresponse. Am J Prev Med 1998
73-7.
Propst T, Propst A, Lhotta K, et al. Reinforced intradermal
hepatitis B vaccination in hemodialysis patients is superior
in antibody response to intramuscular or subcutaneous
vaccination. Am J Kidney Dis 1998; 32:1041-5.
Peces R, de la Torre M, Alcázar R, Urra JM. Prospective
analysis of the factors influencing the antibody response to
hepatitis B vaccine in hemodialysis patients. Am J Kidney
Dis 1997; 29:239-45.
Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic
prediction of nonresponse to hepatitis B vaccine. N Engl J
Med 1989; 321:708-12.
Makidon PE, Bielinska AU, Nigavekar SS, et al. Preclinical
evaluation of a novel nanoemulsion-based hepatitis
B mucosal vaccine. PLoS One 2008; 3:e2954. doi: 10.1371/
journal.pone.0002954
Halperin SA, Ward B, Cooper C, et al. Comparison of safety and
immunogenicity of two doses of investigational hepatitis B virus
surface antigen co-administered with an immunostimulatory
phosphorothioate oligodeoxyribonucleotide and three doses
of a licensed hepatitis B vaccine in healthy adults 18-55
years of age. Vaccine 2012; 30:2556-63. doi: 10.1016/j.
vaccine.2012.01.087
Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of
safety and enhanced seroprotection against hepatitis B with
investigational HBsAg-1018 ISS vaccine compared to a
licensed hepatitis B vaccine. Vaccine 2012;30:2689-96. doi
1016/j.vaccine.2012.02.001
Singh M, Li XM, McGee JP, et al. Controlled release
microparticles as a single dose hepatitis B vaccine: evaluation
of immunogenicity in mice. Vaccine 1997; 15:475-81.
Rahman F, Dahmen A, Herzog-Hauff S, et al. Cellular
and humoral immune responses induced by intradermal or
intramuscular vaccination with the major hepatitis B surface
antigen. Hepatology 2000; 31:521-7.
Rault R, Freed B, Nespor S, Bender F. Efficacy of different
hepatitis B vaccination strategies in patients receiving
hemodialysis. ASAIO J 1995; 41:M717.
Fabrizi F, Dixit V, Magnini M, et al. Meta-analysis
intradermal vs. intramuscular vaccination against hepatitis
B virus in patients with chronic kidney disease. Aliment
Pharmacol Ther 2006; 24:497-506.
Quiroga JA, Carreño V. Interferon and hepatitis B vaccine in
haemodialysis patients. Lancet 1989; 1:1264.
Jungers P, Devillier P, Salomon H, et al. Randomised
placebo-controlled trial of recombinant interleukin-2 in
chronic uraemic patients who are non-responders to hepatitis
B vaccine. Lancet 1994; 344:856.
Thoelen S, Van Damme P, Mathei C, et al. Safety and
immunogenicity of a hepatitis B vaccine formulated with a
novel adjuvant system. Vaccine 1998; 16:708.
Traquina P, Morandi M, Contorni M, Van Nest G. MF59
adjuvant enhances the antibody response to recombinant
hepatitis B surface antigen vaccine in primates. J Infect Dis
174:1168.
Jacques P, Moens G, Desombere I, et al. The immunogenicity
and reactogenicity profile of a candidate hepatitis B vaccine
in an adult vaccine non-responder population. Vaccine 2002
3644.
Sprengers D, Janssen HLA. Immunomodulatory therapy for
chronic hepatitis B virus infection. Fundam Clin Pharmacol
19:17–26
Tozun N, Ozdogan OC, Cakaloglu Y, et al. A nationwide
prevalance study and risk factors for hepatitis A, B, C and
D infections in Turkey. Hepatology Volume 2010; 52
(Supplement S1): 697A.
Houghton M. Prospects for prophylactic and therapeutic
vaccines against the hepatitis C viruses. Immunol Rev 2011
99–108.
Frey SE, Houghton M, Coates S, et al. Safety and
immunogenicity of HCV E1E2 vaccine adjuvanted with
MF59 administered to healthy adults. Vaccine 2010; 28
-73.
Law LMJ, Landi A, Magee WC, Tyrrell DL, Houghton
H. Progress towards a hepatitis C virus vaccine. Emerging
Microbes and Infections 2013;2:e79. doi:10.1038/
emi.2013.79; published online 20 November 2013

There are 113 citations in total.

Details

Subjects	Clinical Sciences
Other ID	JA88NZ27ZH
Journal Section	Reviews
Authors	Merve Poyraz This is me Osman Cavit Özdoğan This is me
Publication Date	August 1, 2016
Published in Issue	Year 2016

Cite

APA	Poyraz, M., & Özdoğan, O. C. (2016). New developments in the era of viral hepatitis vaccines. Marmara Medical Journal, 29(2), 29-32. https://doi.org/10.5472/MMJsi.2901.06
AMA	Poyraz M, Özdoğan OC. New developments in the era of viral hepatitis vaccines. Marmara Med J. August 2016;29(2):29-32. doi:10.5472/MMJsi.2901.06
Chicago	Poyraz, Merve, and Osman Cavit Özdoğan. “New Developments in the Era of Viral Hepatitis Vaccines”. Marmara Medical Journal 29, no. 2 (August 2016): 29-32. https://doi.org/10.5472/MMJsi.2901.06.
EndNote	Poyraz M, Özdoğan OC (August 1, 2016) New developments in the era of viral hepatitis vaccines. Marmara Medical Journal 29 2 29–32.
IEEE	M. Poyraz and O. C. Özdoğan, “New developments in the era of viral hepatitis vaccines”, Marmara Med J, vol. 29, no. 2, pp. 29–32, 2016, doi: 10.5472/MMJsi.2901.06.
ISNAD	Poyraz, Merve - Özdoğan, Osman Cavit. “New Developments in the Era of Viral Hepatitis Vaccines”. Marmara Medical Journal 29/2 (August 2016), 29-32. https://doi.org/10.5472/MMJsi.2901.06.
JAMA	Poyraz M, Özdoğan OC. New developments in the era of viral hepatitis vaccines. Marmara Med J. 2016;29:29–32.
MLA	Poyraz, Merve and Osman Cavit Özdoğan. “New Developments in the Era of Viral Hepatitis Vaccines”. Marmara Medical Journal, vol. 29, no. 2, 2016, pp. 29-32, doi:10.5472/MMJsi.2901.06.
Vancouver	Poyraz M, Özdoğan OC. New developments in the era of viral hepatitis vaccines. Marmara Med J. 2016;29(2):29-32.

Article Files

Full Text